CD274 and pancreatic adenocarcinoma: The response to PD-1/PD-L1 inhibition has been mixed in various malignancies such as colorectal, prostatic and pancreatic adenocarcinomas and is exemplified in the results of a study by Brahmer et al. which failed to show an objective response to anti-PD-L1 therapy in 14 patients with pancreatic cancer [3, 10].